Risks of any grade pruritus (RR: 1.93 (95% CI 1.40-2.67) p < 0.00001 Supplementary Figure 5A) and any grade rash [RR: 1.28 (95% CI 1.03-1.58) p < 0.00001 Supplementary Figure 5B] developed during PD-1 inhibitor therapy were decreased compared to PD-L1 inhibitor. Here, CD274 is linked to Pruritus.